Get started
Author

David M. Cross

Observed names: Cross, David M., D Cross, D. M. CROSS, D. M. Cross, D.M. Cross, DAVID M. CROSS, David M. Cross
OpenAlex ID: A5017378285
Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
2008 · Paul G. Wyatt, Andrew J. Woodhead, et al. · Journal of Medicinal Chemistry · 346
Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity
2008 · Steven Howard, Valerio Berdini, et al. · Journal of Medicinal Chemistry · 336
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
2009 · Matthew S. Squires, Ruth E. Feltell, et al. · Molecular Cancer Therapeutics · 172
From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease
2021 · Alastair J.H. Brown, Sophie J. Bradley, et al. · Cell · 100
A Commentary on the Use of Hepatocytes in Drug Metabolism Studies During Drug Discovery and Development*
2000 · D. M. CROSS, M. K. BAYLISS · Drug Metabolism Reviews · 83
The heat shock protein 90 inhibitor, AT 13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer
2011 · Brent Graham, Jayne Curry, et al. · Cancer Science · 81
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension
2012 · Keith Owen, David M. Cross, et al. · Regulatory Toxicology and Pharmacology · 27
Adenosine triphosphate as an indicator of cellular toxicity In vitro
1986 · R.B. Kemp, D.M. Cross, et al. · Food and Chemical Toxicology · 23
First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias
2020 · Charlotte Bakker, Tim Tasker, et al. · British Journal of Clinical Pharmacology · 16
PDF
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study
2021 · Charlotte Bakker, Tim Tasker, et al. · Alzheimer s Research & Therapy · 15
PDF
Comparison of cell death and adenosine triphosphate content as indicators of acute toxicity in vitro
1988 · R. B. Kemp, D. M. Cross, et al. · Xenobiotica · 14
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M 1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease
2022 · Pradeep J. Nathan, S. Babli Millais, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 13
PDF
An Evaluation of Reproductive and Developmental Toxicity of Sitaxentan ( T helin) in Rats
2012 · David M. Cross, Elizabeth Horsley, et al. · Birth Defects Research Part B Developmental and Reproductive Toxicology · 12
Tissue Distribution of Anidulafungin in Neonatal Rats
2012 · Sharon L. Ripp, Jalal A. Aram, et al. · Birth Defects Research Part B Developmental and Reproductive Toxicology · 12
Kinetics of ranitidine metabolism in dog and rat isolated hepatocytes
1995 · D. M. Cross, J. A. Bell, et al. · Xenobiotica · 10
Juvenile toxicity assessment of anidulafungin in rats: an example of navigating case-by-case study design through scientific and regulatory challenges
2011 · Christopher J. Bowman, Gary Chmielewski, et al. · Birth Defects Research Part B Developmental and Reproductive Toxicology · 9
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: A randomized cross‐over trial
2021 · Charlotte Bakker, Samantha Prins, et al. · British Journal of Clinical Pharmacology · 8
PDF
Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency pediatric investigation plan
2012 · David M. Cross, Mazin Derzi, et al. · Regulatory Toxicology and Pharmacology · 6
Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects
2021 · Charlotte Bakker, Jasper van der Aart, et al. · Drugs in R&D · 5
PDF
Non-clinical safety assessment and toxicokinetics of voriconazole and anidulafungin in the juvenile rat: A combination study design in support of a Paediatric Investigation Plan
2012 · David M. Cross, Gary Chmielewski, et al. · Regulatory Toxicology and Pharmacology · 4
Drug–drug Interactions
2004 · M Bayliss, D Cross · CRC Press eBooks · 3
Efficacy and safety of fluvastatin ER 80 mg compared with fluvastatin IR 40 mg in the treatment of primary hypercholesterolaemia
2004 · William Insull, A. David Marais, et al. · British Journal of Cardiology · 3
The importance of hepatocytes in drug metabolism studies: an industrial perspective
2000 · Martin K. Bayliss, David M. Cross · Springer eBooks · 2
From Structure to Clinic: Discovery of A M1 Muscarinic Acetylcholine Receptor Agonist for the Treatment of Memory Loss in Alzheimer's Disease
2020 · Alastair J. H. Brown, Sophie J. Bradley, et al. · SSRN Electronic Journal · 1
Enzymology of ranitidine metabolism in isolated hepatocytes from dog
1990 · DAVID M. CROSS, KEITH WILSON, et al. · Biochemical Society Transactions · 1
Works count: 35
Citation count: 1,302
H-index: 12
I10-index: 15
Year
Topic
Type